WisdomTree U.S. SmallCap Quality Dividend Growth Fund (DGRS): outlook, holdings and fees
WisdomTree U.S. SmallCap Quality Dividend Growth Fund (DGRS) is an exchange-traded fund and is managed by WisdomTree. The expense ratio is 0.37% and the yield is 1.99%. The ten largest holdings are 19% of the fund.
Fund data as of Oct 14, 2026 · Price Nov 2, 2026
ATLAS view on DGRS
| Last price | $59.09 (+2.4%) |
|---|---|
| ATLAS chance of a higher price in 1 month | 56% |
| Likely 1-month range (50%) | $57.96 – $60.85 |
| Normal 1-day range (±1σ) | ±0.8% |
| Distribution yield | 1.99% · monthly |
ATLAS probabilities use the same calibrated model as every stock page. A fair value is shown for companies, not funds; the holdings below link to the fair value of each company.
DGRS fund facts
| Issuer | WisdomTree |
|---|---|
| Theme | US large caps |
| Assets under management | $383M |
| Expense ratio | 0.37% |
| Number of holdings | 50 |
| Portfolio turnover | 53% |
| Inception | Jul 25, 2013 |
| Exchange | NASDAQ |
The fund invests, under normal circumstances, at least 80% of its net assets, plus any borrowings for investment purposes, in constituents of the index and/or investments that have economic characteristics that are substantially similar to the economic characteristics of such constituents. The index is based on a rules-based methodology overseen and implemented by the WisdomTree U.S. Dividend Index Committee. It is non-diversified.
DGRS top holdings
| Holding | Sector | Weight |
|---|---|---|
| Avnet Inc AVT | Technology | 3.00% |
| Victory Capital Holdings Inc VCTR | Financial Services | 2.63% |
| Archrock Inc AROC | Energy | 2.28% |
| California Resources Corp CRC | Energy | 1.79% |
| Inter Parfums Inc IPAR | Consumer Defensive | 1.77% |
| Cohen & Steers Inc CNS | Financial Services | 1.61% |
| The Cheesecake Factory CAKE | Consumer Cyclical | 1.48% |
| Northern Oil & Gas Inc NOG | Energy | 1.44% |
| Independent Bank INDB | Financial Services | 1.49% |
| Buckle Inc BKE | Consumer Cyclical | 1.50% |
Holdings with an ATLAS page link to their probability range, fair value and earnings calendar.
DGRS sector breakdown
| Sector | Weight |
|---|---|
| Financial Services | 25.7% |
| Industrials | 19.6% |
| Consumer Cyclicals | 16.6% |
| Energy | 10.8% |
| Technology | 9.6% |
| Basic Materials | 7.4% |
| Consumer Defensive | 5.0% |
| Communication Services | 2.4% |
| Real Estate | 1.9% |
| Healthcare | 0.8% |
| Utilities | 0.2% |
By region: North America 99.8%, Latin America 0.2%.
DGRS returns and risk
| Year to date | +16.0% |
|---|---|
| 1 year | +17.9% |
| 3 years (annualised) | +15.5% |
| 5 years (annualised) | +7.1% |
| 10 years (annualised) | +9.6% |
| Volatility (3 years) | 19.6% |
| Sharpe ratio (3 years) | 0.53 |
Past returns do not guarantee future results.
DGRS: frequently asked questions
What does DGRS invest in?
WisdomTree U.S. SmallCap Quality Dividend Growth Fund invests in a portfolio of securities. Its largest holdings are Avnet Inc (3.0%), Victory Capital Holdings Inc (2.6%), Archrock Inc (2.3%), California Resources Corp (1.8%), Inter Parfums Inc (1.8%).
What is the DGRS expense ratio?
0.37% a year: about $37.00 for every $10,000 invested.
What is the DGRS dividend yield?
1.99%, paid monthly. ATLAS does not hold the exact distribution dates for ETFs.
Will DGRS go up?
Nobody can know. The ATLAS model puts the chance of a higher price in one month at 56%, with a likely range (50%) of $57.96 to $60.85 from $59.09 today. It is a probability, not a prediction.
How has DGRS performed?
Year to date +16.0%, one year +17.9%, three years +15.5% a year, five years +7.1% a year. Past returns do not guarantee future results.
Similar ETFs: US large caps
- Vanguard Total Stock Market ETF (VTI)
- Schwab U.S. Dividend Equity ETF (SCHD)
- iShares Core S&P Total U.S. Stock Market ETF (ITOT)
- Schwab U.S. Large-Cap ETF (SCHX)
- Schwab U.S. Large-Cap Growth ETF (SCHG)
- Vanguard Morningstar Large-Cap ETF (VV)
- Dimensional U.S. Core Equity 2 ETF (DFAC)
- iShares MSCI USA Quality Factor ETF (QUAL)
Educational information, not investment advice. Disclaimer